LY03017 vs Roluperidone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Serotonin 5-HT2A receptor (antagonist / inverse agonist) · full Schizophrenia pipeline

LY03017

Developed by Luye Pharma Group

Phase 1 in Schizophreniasmall molecule
Weak signal

NCT06388551 · Phase 1 · status unknown

This early-phase study randomly assigned healthy volunteers to ascending single oral doses of LY03017 or matching placebo under quadruple-blind conditions, tracking adverse events as the primary outcome. No results have been posted, so it remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. Its registered primary outcome on ClinicalTrials.gov is "Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Roluperidone

Developed by Minerva Neurosciences

Phase 3 in Schizophreniasmall molecule
Partial signal

NCT03397134 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 efficacy trial with an adequate sample (513 patients) and a hard clinical primary endpoint: change in the validated PANSS Marder negative symptom factor score (NSFS) at 12 weeks. However, the primary endpoint comparison was not met under the protocol's predefined multiplicity-adjusted threshold (64 mg vs placebo p=0.043 exceeded the required p≤0.025), and the 32 mg dose showed essentially no separation from placebo. Because the primary result was non-significant, the trial provides real but limited evidence despite its strong design.

Next expected readout: December 2027 · NCT07565428 (registry estimate)

Reported efficacy

Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) (missed)

Result source: NCT03397134

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLY03017Roluperidone
PANSS total, change—Not reported—Trial running · NCT07565428
CGI-S, change—Not reported-0.4 vs -0.3−0.1 vs placebo64 mg · wk 12 · n 171NCT03397134
7 other results
  • -0.4 vs -0.2 64 mg · wk 8 · n 171 · Phase 3 · secondary NCT03397134
  • -0.3 vs -0.1 64 mg · wk 4 · n 171 · Phase 3 · secondary NCT03397134
  • -0.1 vs -0.1 64 mg · wk 2 · n 171 · Phase 3 · secondary NCT03397134
  • -0.4 vs -0.3 32 mg · wk 12 · n 170 · Phase 3 · secondary NCT03397134
  • -0.3 vs -0.2 32 mg · wk 8 · n 170 · Phase 3 · secondary NCT03397134
  • -0.2 vs -0.1 32 mg · wk 4 · n 170 · Phase 3 · secondary NCT03397134
  • -0.1 vs -0.1 32 mg · wk 2 · n 170 · Phase 3 · secondary NCT03397134
PANSS response—Not reported—Trial running · NCT07565428
PSP, change—Not reported5 vs 3.1+1.9 vs placebo64 mg · wk 8 · n 162NCT03397134
3 other results
  • 3.2 vs 1.2 64 mg · wk 4 · n 162 · Phase 3 · secondary NCT03397134
  • 3.6 vs 3.1 32 mg · wk 8 · n 167 · Phase 3 · secondary NCT03397134
  • 1.6 vs 1.2 32 mg · wk 4 · n 167 · Phase 3 · secondary NCT03397134
Relapse (% of patients)—Not reported—Trial running · NCT07565428

PANSS total, change

LY03017
—Not reported
Roluperidone
—Trial running · NCT07565428

CGI-S, change

LY03017
—Not reported
Roluperidone
-0.4 vs -0.3−0.1 vs placebo64 mg · wk 12 · n 171NCT03397134
7 other results
  • -0.4 vs -0.2 64 mg · wk 8 · n 171 · Phase 3 · secondary NCT03397134
  • -0.3 vs -0.1 64 mg · wk 4 · n 171 · Phase 3 · secondary NCT03397134
  • -0.1 vs -0.1 64 mg · wk 2 · n 171 · Phase 3 · secondary NCT03397134
  • -0.4 vs -0.3 32 mg · wk 12 · n 170 · Phase 3 · secondary NCT03397134
  • -0.3 vs -0.2 32 mg · wk 8 · n 170 · Phase 3 · secondary NCT03397134
  • -0.2 vs -0.1 32 mg · wk 4 · n 170 · Phase 3 · secondary NCT03397134
  • -0.1 vs -0.1 32 mg · wk 2 · n 170 · Phase 3 · secondary NCT03397134

PANSS response

LY03017
—Not reported
Roluperidone
—Trial running · NCT07565428

PSP, change

LY03017
—Not reported
Roluperidone
5 vs 3.1+1.9 vs placebo64 mg · wk 8 · n 162NCT03397134
3 other results
  • 3.2 vs 1.2 64 mg · wk 4 · n 162 · Phase 3 · secondary NCT03397134
  • 3.6 vs 3.1 32 mg · wk 8 · n 167 · Phase 3 · secondary NCT03397134
  • 1.6 vs 1.2 32 mg · wk 4 · n 167 · Phase 3 · secondary NCT03397134

Relapse (% of patients)

LY03017
—Not reported
Roluperidone
—Trial running · NCT07565428
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

LY03017: no structured comparison results are available for Schizophrenia.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Roluperidone

PANSS NSFS -1.7 vs -1.2 placebo score @ 2wk64 mg
absolute change · score
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 7 more results
-2.8 vs -1.8 placebo score @ 4wk64 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-3.8 vs -2.8 placebo score @ 8wk64 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-4.5 vs -3.5 placebo score @ 12wk64 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -1.2 placebo score @ 2wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-2.6 vs -1.8 placebo score @ 4wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-3.4 vs -2.8 placebo score @ 8wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-3.7 vs -3.5 placebo score @ 12wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
PSP 3.2 vs 1.2 placebo score @ 4wk64 mg
absolute change · score
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 3 more results
5 vs 3.1 placebo score @ 8wk64 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.6 vs 1.2 placebo score @ 4wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.6 vs 3.1 placebo score @ 8wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
PSP 6.2 vs 4.2 placebo score @ 12wk64 mg
absolute change · score
hange from Baseline to Week 12
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 1 more result
4.6 vs 4.2 placebo score @ 12wk32 mg
hange from Baseline to Week 12
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.1 vs -0.1 placebo score @ 2wk64 mg
absolute change · score
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 7 more results
-0.3 vs -0.1 placebo score @ 4wk64 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -0.2 placebo score @ 8wk64 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -0.3 placebo score @ 12wk64 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.1 vs -0.1 placebo score @ 2wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.2 vs -0.1 placebo score @ 4wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.3 vs -0.2 placebo score @ 8wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -0.3 placebo score @ 12wk32 mg
NCT03397134 · Phase 3 · monotherapy · Schizophrenia · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03017's landscape · Roluperidone's landscape